- Athira shares plunged over 39% on June 18 after founder/CEO Leen Kawas was placed on temporary leave due to an ongoing review into her doctoral research at Washington State University.
- The review is examining potential misconduct stemming from allegations of altered images in her doctoral dissertation and several other research papers published from 2011-2012.
- In this article, I review the relevance of the disputed research to Athira’s ongoing trials and attempt to assess whether this is a ticking time bomb or a buying opportunity.
For further details see:
Athira Pharma - ATH-1017: Panacea Or Pandora's Box?